Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel

被引：0
|
作者：
O'Brien, CA
Garzotto, M
Higano, CS
Wersinger, EM
Kaimaktchiev, V
Corless, CL
Lange, PH
Ryan, CW
Beer, TM
机构：
[1] Oregon Hlth Sci Univ, Portland VA Med, Portland, OR 97201 USA
[2] Univ Washington, Sch Med, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：412S / 412S
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Garzotto, M
    Myrthue, A
    Higano, CS
    Beer, TM
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (03) : 254 - 259
  • [2] Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer
    Friedman, Judah
    Dunn, Rodney L.
    Wood, David
    Vaishampayan, Ulka
    Wu, Angela
    Bradley, Deborah
    Montie, James
    Sarkar, Fazlul H.
    Shah, Rajal B.
    Hussain, Maha
    [J]. JOURNAL OF UROLOGY, 2008, 179 (03): : 911 - 915
  • [3] Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer
    Rademacher, B. L.
    Garzotto, M.
    Higano, C. S.
    O'Brien, C. A.
    Janeba, N.
    Fazli, L.
    Lange, P. H.
    Lieberman, S.
    Beer, T. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer - Comment
    Morris, Michael J.
    [J]. JOURNAL OF UROLOGY, 2008, 179 (03): : 915 - 916
  • [5] Weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer
    Beer, TM
    Garzotto, M
    Lowe, BA
    Ellis, WJ
    Lange, PH
    Montalto, MA
    Higano, C
    [J]. JOURNAL OF UROLOGY, 2003, 169 (04): : 444 - 444
  • [6] Predictors of PSA relapse in patients with intermediate risk prostate cancer treated with SBRT
    Kole, T.
    Guleria, S.
    Koneru, H.
    Obayomi-Davies, O.
    Yung, T.
    Lei, S.
    Collins, B.
    Suy, S.
    Dritschilo, A.
    Collins, S.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S344 - S345
  • [7] Early relapse and predictors of relapse-free survival in neoadjuvant chemotherapy-treated breast cancer patients
    Martin, Natalie
    Pasztorova, Julia
    Hibell, Isabella
    Wheatley, Duncan
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [8] Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer
    Febbo, PG
    Richie, JP
    George, DJ
    Loda, M
    Manola, J
    Shankar, S
    Barnes, AS
    Tempany, C
    Catalona, W
    Kantoff, PW
    Oh, WK
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (14) : 5233 - 5240
  • [9] Phase 1/2 Study of Preoperative Docetaxel and Mitoxantrone for High-Risk Prostate Cancer
    Garzotto, Mark
    Higano, Celestia S.
    O'Brien, Catherine
    Rademacher, Brooks L. S.
    Janeba, Nicole
    Fazli, Ladan
    Lange, Paul H.
    Lieberman, Stephen
    Beer, Tomasz M.
    [J]. CANCER, 2010, 116 (07) : 1699 - 1708
  • [10] Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
    Qu, Feng
    Gu, Yue
    Xue, Mengxia
    He, Mingzhe
    Zhou, Fang
    Wang, Guangji
    Peng, Ying
    [J]. PROSTATE, 2021, 81 (09): : 560 - 571
12345